Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2015 Apr 29

PMID 25918181

Citations 220

Authors

Kwonjune J Seung

Salmaan Keshavjee

Michael L Rich

Affiliations

Soon will be listed here.

Abstract

The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control. Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. In 2012, there were approximately 450,000 new cases and 170,000 deaths because of MDR-TB. Extensively drug-resistant (XDR) TB refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs. The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. Although patients harboring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen. Community-based programs can improve treatment outcomes by allowing patients to be treated in their homes and addressing socioeconomic barriers to adherence.

Citing Articles

Supradecoration induced homogenous electrochemical sensing: development of Ru(ii) half sandwich complex as isoniazid and rifampicin dual sensor.

Mustafa M, Jan T, Rohullah M, Masoodi M, Din Reshi N, Rizvi M RSC Adv. 2025; 15(9):7004-7017.

PMID: 40041381 PMC: 11877425. DOI: 10.1039/d4ra07773c.

Development and validation of a nomogram predicting multidrug-resistant tuberculosis risk in East China.

He F, Wang S, Wang H, Ding X, Huang P, Fan X PeerJ. 2025; 13:e19112.

PMID: 40034676 PMC: 11874934. DOI: 10.7717/peerj.19112.

Geographical location and genotyping analysis of pulmonary tuberculosis in the state of Nuevo Leon, Mexico.

Zacarias-Hernandez J, Flores-Arechiga A, Tamez-Guerra R, Rivera-Morales L, Castro-Garza J, Becerril-Montes P Sci Rep. 2025; 15(1):7098.

PMID: 40016307 PMC: 11868510. DOI: 10.1038/s41598-025-90579-y.

Glutathione Depletion Exacerbates Hepatic Infection.

Sasaninia K, Mohan A, Badaoui A, Glassman I, Yoon S, Karapetyan A Biology (Basel). 2025; 14(2).

PMID: 40001899 PMC: 11852144. DOI: 10.3390/biology14020131.

Efficacy and safety data on pretomanid for drug-resistant TB.

Thuy H, Padmapriyadarsini C, Chuchottaworn C, Foraida S, Hadigal S, Birajdar A IJTLD Open. 2025; 2(2):73-82.

PMID: 39959405 PMC: 11827665. DOI: 10.5588/ijtldopen.24.0360.

References

Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, Lalloo U . Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547):1575-80. DOI: 10.1016/S0140-6736(06)69573-1. View

Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K . Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006; 10(6):605-12. View

Frieden T, Sterling T, Pablos-Mendez A, Kilburn J, Cauthen G, DOOLEY S . The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993; 328(8):521-6. DOI: 10.1056/NEJM199302253280801. View

Becerra M, Franke M, Appleton S, Joseph J, Bayona J, Atwood S . Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2012; 32(2):115-9. DOI: 10.1097/INF.0b013e31826f6063. View

Cegielski J . Extensively drug-resistant tuberculosis: "there must be some kind of way out of here". Clin Infect Dis. 2010; 50 Suppl 3:S195-200. DOI: 10.1086/651491. View

Pomerantz B, Cleveland Jr J, Olson H, Pomerantz M . Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg. 2001; 121(3):448-53. DOI: 10.1067/mtc.2001.112339. View

Gelmanova I, Keshavjee S, Golubchikova V, Berezina V, Strelis A, Yanova G . Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ. 2007; 85(9):703-11. PMC: 2636414. DOI: 10.2471/blt.06.038331. View

Satti H, McLaughlin M, Seung K, Becerra M, Keshavjee S . High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2012; 17(1):100-6. DOI: 10.5588/ijtld.12.0344. View

Wells C, Cegielski J, Nelson L, Laserson K, Holtz T, Finlay A . HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007; 196 Suppl 1:S86-107. DOI: 10.1086/518665. View

10.

Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Van Gemert W . Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J. 2011; 39(6):1425-31. PMC: 3393766. DOI: 10.1183/09031936.00145411. View

11.

Shin S, Pasechnikov A, Gelmanova I, Peremitin G, Strelis A, Mishustin S . Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006; 10(4):402-8. View

12.

PYLE M . Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet Mayo Clin. 2010; 22(21):465-73. View

13.

. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013; 62(RR-09):1-12. View

14.

Keshavjee S, Farmer P . Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med. 2012; 367(10):931-6. DOI: 10.1056/NEJMra1205429. View

15.

Lin H, Shin S, Blaya J, Zhang Z, Cegielski P, Contreras C . Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiol Infect. 2011; 139(11):1784-93. PMC: 3153578. DOI: 10.1017/S0950268810002797. View

16.

Chavez Pachas A, Blank R, Smith Fawzi M, Bayona J, Becerra M, Mitnick C . Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis. 2004; 8(1):52-8. View

17.

Mukherjee J, Rich M, Socci A, Joseph J, Viru F, Shin S . Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004; 363(9407):474-81. DOI: 10.1016/S0140-6736(04)15496-2. View

18.

Zhao Y, Xu S, Wang L, Chin D, Wang S, Jiang G . National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012; 366(23):2161-70. DOI: 10.1056/NEJMoa1108789. View

19.

Dye C, Williams B, Espinal M, Raviglione M . Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 2002; 295(5562):2042-6. DOI: 10.1126/science.1063814. View

20.

Frieden T, Fujiwara P, Washko R, Hamburg M . Tuberculosis in New York City--turning the tide. N Engl J Med. 1995; 333(4):229-33. DOI: 10.1056/NEJM199507273330406. View